AS
ASMB
ASSEMBLY BIOSCIENCES, INC.
$22.56
-1.48%
$358.5M
No data for this timeframe.
Vol
Market Cap$358.5M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders5 funds
Inst. Value$21.0M
Inst. Activity3 buys / 1 sells
Insider Activity0B / 2S
Insider Net $-$13.3K
SEC Reports5
Press Releases2
Recent Activity
Jun 5, 2026
SEC
Assembly Biosciences held its 2026 annual meeting on June 4, 2026, where stockholders approved an increase in shares res
8-K — Impact 2/10
Jun 4, 2026
Insider
McHutchison John G sold 8,000 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
Mahony Susan sold 8,000 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
Johnson-Pratt Lisa sold 8,000 shares
Director @ $0.00 ($0.00)
May 28, 2026
other
Assembly Biosciences Announces Upcoming Investor Conference Presentations
<p>SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasda
May 22, 2026
SEC
Assembly Biosciences (ASMB) filed a preliminary prospectus supplement for an underwritten public offering of common stoc
424B5 — Impact 6/10
May 22, 2026
SEC
Assembly Biosciences announced plans to expand clinical development of ABI-6250, its oral NTCP inhibitor, from chronic h
8-K — Impact 5/10
Inst.
MORGAN STANLEY — DOUBLED
22,534 shares ($766.4K)
Price Targets
$48.75
+114.6% upside
Strong Buy
Current $22.72
Low $40.00
Median $46.50
High $62.00
4 analysts
$40.00
$62.00
Analyst Ratings
4Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 28, 2026 | Guggenheim | REITERATE | Buy → Buy |
| May 4, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 6, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
| Mar 26, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Dec 22, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.53 ▲ +22.4% | $-0.70 — $-0.35 | 61% YoY | 2 |
| Next Q | $-0.51 ▲ +24.6% | $-0.69 — $-0.32 | 30% YoY | 2 |
| Current FY | $0.14 ▲ +111.4% | $-1.62 — $1.90 | 125% YoY | 2 |
| Next FY | $-2.71 ▼ -17.3% | $-3.92 — $-0.77 | -2036% YoY | 3 |
Latest Reports
NEUTRAL
8-K
2/10
Assembly Biosciences held its 2026 annual meeting on June 4, 2026, where stockholders approved an increase in shares res
Jun 5, 2026
BEARISH
424B5
6/10
Assembly Biosciences (ASMB) filed a preliminary prospectus supplement for an underwritten public offering of common stoc
May 22, 2026
NEUTRAL
Press
5/10
Assembly Bio is expanding ABI-6250, an oral NTCP inhibitor in Phase 1a for HDV, into cholestatic liver diseases (PBC/PSC
May 22, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $19.5M | ADD |
| MORGAN STANLEY | $766.4K | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $314.3K | NEAR_EXIT |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $228.0K | NEW |
| BANK OF AMERICA CORP | $173.8K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | McHutchison John | A | $0.00 |
| Jun 4, 2026 | Mahony Susan | A | $0.00 |
| Jun 4, 2026 | Johnson-Pratt Lisa | A | $0.00 |
| Jun 4, 2026 | Houghton Michael | A | $0.00 |
| Jun 4, 2026 | Consylman Gina | A | $0.00 |
5 institutional holders with $21.0M total value (616,486 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, RENAISSANCE. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 572,898 | $19.5M | 92.9% | ADD +97.8% |
| 2 | MORGAN STANLEY | 22,534 | $766.4K | 3.7% | DOUBLED +538.9% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 9,240 | $314.3K | 1.5% | NEAR_EXIT -94.0% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 6,704 | $228.0K | 1.1% | NEW |
| 5 | BANK OF AMERICA CORP /DE/ | 5,110 | $173.8K | 0.8% | ADD +51.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 3,527 | 22,534 | +538.9% | $766.4K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 153,611 | 9,240 | -94.0% | $314.3K | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 6,704 | — | $228.0K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 3,371 | 5,110 | +51.6% | $173.8K | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 253,825 | 502,112 | +97.8% | $12.9M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 107,521 | 153,611 | +42.9% | $3.9M | 2025-Q3 |
| UBS Group AG | DOUBLED | 2,933 | 15,763 | +437.4% | $403.5K | 2025-Q3 |
| MORGAN STANLEY | ADD | 2,149 | 3,527 | +64.1% | $90.3K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 52 | 3,371 | +6382.7% | $86.3K | 2025-Q3 |
| UBS Group AG | DOUBLED | 767 | 2,933 | +282.4% | $53.1K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 39 | 52 | +33.3% | $942.00 | 2025-Q2 |
| FMR LLC | EXIT | 5,659 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | NEW | — | 12,258 | — | $117.2K | 2025-Q1 |
| FMR LLC | TRIM | 17,566 | 5,659 | -67.8% | $54.1K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 6,547 | 767 | -88.3% | $7.3K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 65,624 | 94,711 | +44.3% | $1.5M | 2024-Q4 |
| UBS Group AG | DOUBLED | 1,301 | 6,547 | +403.2% | $103.3K | 2024-Q4 |
| CITADEL ADVISORS LLC | EXIT | 12,720 | 0 | -100.0% | $0.00 | 2024-Q4 |
12 unique insiders with 2 transactions. Net insider value: -$13.3K ($0.00 bought, $13.3K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | McHutchison John G | Director | A | 8,000 | $0.00 | $0.00 |
| Jun 4, 2026 | Mahony Susan | Director | A | 8,000 | $0.00 | $0.00 |
| Jun 4, 2026 | Johnson-Pratt Lisa | Director | A | 8,000 | $0.00 | $0.00 |
| Jun 4, 2026 | Houghton Michael | Director | A | 8,000 | $0.00 | $0.00 |
| Jun 4, 2026 | Consylman Gina | Director | A | 8,000 | $0.00 | $0.00 |
| Jun 4, 2026 | ALTIG ANTHONY E | Director | A | 8,000 | $0.00 | $0.00 |
| May 26, 2026 | GILEAD SCIENCES, INC. | 10%+ Owner | A | 471,698 | $26.50 | $12.5M |
| Mar 30, 2026 | White Nicole S | Chief Manufacturing Officer | SELL | 188 | $26.65 | $5.0K |
| Mar 30, 2026 | Bjorkquist Jeanette M | PFO and PAO | SELL | 312 | $26.65 | $8.3K |
| Mar 29, 2026 | Gaggar Anuj | Chief Medical Officer | A | 14,000 | $0.00 | $0.00 |
| Mar 29, 2026 | White Nicole S | Chief Manufacturing Officer | A | 14,000 | $0.00 | $0.00 |
| Mar 29, 2026 | Bjorkquist Jeanette M | PFO and PAO | A | 3,500 | $0.00 | $0.00 |
| Mar 29, 2026 | Delaney William E IV | Chief Scientific Officer | A | 14,000 | $0.00 | $0.00 |
| Mar 29, 2026 | Bjorkquist Jeanette M | PFO and PAO | A | 6,500 | $0.00 | $0.00 |
| Mar 29, 2026 | White Nicole S | Chief Manufacturing Officer | A | 26,000 | $0.00 | $0.00 |
| Mar 29, 2026 | Okazaki Jason A | CEO and President | A | 94,250 | $0.00 | $0.00 |
| Mar 29, 2026 | Delaney William E IV | Chief Scientific Officer | A | 26,000 | $0.00 | $0.00 |
| Mar 29, 2026 | Gaggar Anuj | Chief Medical Officer | A | 26,000 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 4.4/10.
NEUTRAL
8-K
2/10
Assembly Biosciences held its 2026 annual meeting on June 4, 2026, where stockholders approved an in
Jun 5, 2026
BEARISH
424B5
6/10
Assembly Biosciences (ASMB) filed a preliminary prospectus supplement for an underwritten public off
May 22, 2026
NEUTRAL
8-K
5/10
Assembly Biosciences announced plans to expand clinical development of ABI-6250, its oral NTCP inhib
May 22, 2026
BULLISH
PRESS-RELEASE
6/10
Assembly Biosciences reported Q1 2026 EPS of -$0.54, beating consensus of -$0.73 by 26%, while colla
May 7, 2026
NEUTRAL
EFFECT
3/10
Assembly Biosciences' $400 million shelf registration (S-3) has become effective, allowing the compa
Mar 30, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 4 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$48.75 mean target
+114.6% upside
Strong Buy (1.00)
$40.00 Low
$62.00 High
| Metric | Value |
|---|---|
| Current Price | $22.72 |
| Target Low | $40.00 |
| Target Mean | $48.75 |
| Target Median | $46.50 |
| Target High | $62.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.53 | $-0.70 | $-0.35 | 60.5% | +22.4% | 1↑ 1↓ | $0.0B | -10.7% | 2 |
| Next Q 2026-09-30 |
$-0.51 | $-0.69 | $-0.32 | 29.9% | +24.6% | 1↑ 0↓ | $0.0B | -23.4% | 2 |
| Current FY 2026-12-31 |
$0.14 | $-1.62 | $1.90 | 125.4% | +111.4% | 2↑ 0↓ | $0.1B | -19.8% | 2 |
| Next FY 2027-12-31 |
$-2.71 | $-3.92 | $-0.77 | -2035.7% | -17.3% | 0↑ 2↓ | $0.0B | -44.4% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.525 | |
| 7d ago | $-0.565 | +0.040 |
| 30d ago | $-0.677 | +0.152 |
| 60d ago | $-0.845 | +0.320 |
| 90d ago | $-0.490 | -0.035 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 28, 2026 | Guggenheim | REITERATE | Buy | Buy |
| May 4, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 6, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Mar 26, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 22, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 28, 2026
other
Assembly Biosciences Announces Upcoming Investor Conference Presentations
<p>SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innov
May 26, 2026
other
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
<p>SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innov
May 22, 2026
other
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
<p>SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innov
May 22, 2026
fda
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
<p align="center"><em>– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 –</em><br><em>– Builds
May 13, 2026
other
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
<p>SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innov
May 11, 2026
other
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
<p>SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innov
May 7, 2026
earnings
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
<p align="center"><em>– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes –</em></p>
May 6, 2026
earnings_calendar
ASMB Q1 2026 Earnings Scheduled — 2026-05-06
Mar 19, 2026
earnings
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
<p align="center"><em>– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366
Mar 18, 2026
earnings_calendar
ASMB Q4 2025 Earnings After Market Close — 2026-03-18